Tuesday broker round-up
15th Nov 2016 12:30
(ShareCast News) - Dairy Crest: Jefferies downgrades to underperform with a target price of 500p. Royal Dutch Shell: HSBC reiterates buy with a 2360p target. Polymetal: Jefferies stays at underperform with a 700p target. Tesco: Credit Suisse reiterates underperform with a 130p target. Paddy Power
Read moreLondon close: Blue chips slide, led by gold-exposed miners amid profit-taking
10th Nov 2016 17:01
(ShareCast News) - London blue-chip stocks fell on Thursday as traders took profits stoked by Donald Trump's election win, with gold-exposed miners, pharmaceutical and US rates-sensitive utilities all flopping. The FTSE 100 ended the session down 1.21% to 6,827.98 points, somewhat out of kilter with
Read moreAstrazeneca reports worse-than-expected drop in Q3 revenue
10th Nov 2016 08:41
(ShareCast News) - Astrazeneca shares edged lower on Thursday as it reported a worse-than-expected drop in third quarter revenue. Revenue fell 4% to $5.7bn in the three months ended 30 September, missing forecasts of $5.87bn, as cheaper generic versions of its best-selling medicine Crestor hurt sale
Read moreAnalysts pick winners as pharma sector bounces back on Clinton loss
9th Nov 2016 13:58
(ShareCast News) - The pharmaceuticals sector bounced back after Donald Trump won the battle to become the next president of the United States and the Republican party won control of Congress, with analysts suggesting AstraZeneca, Shire and Eli Lilly were among the best placed stocks to capitalise o
Read moreThursday preview: Astrazeneca to report decline in third quarter sales
9th Nov 2016 12:31
(ShareCast News) - Astrazeneca is expected to report a drop in third quarter sales on Thursday after failing to prevent generic drug makers from bringing cheaper rivals of its best-selling medicine Crestor. Analysts expect generic versions of cholesterol fighting drug Crestor will have sent revenue
Read moreFriday broker round-up
28th Oct 2016 15:33
(ShareCast News) - Barclays: JP Morgan keeps at neutral with a target price of 190p. Standard Life: Jefferies stays at buy, 391p target. Senior: Berenberg reiterates buy with a 220p target. Imperial Brands: Deutsche Bank reiterates buy with a 4600p target. ITV: Credit Suisse reiterates outperform
Read moreAstraZeneca reports positive results for ovarian cancer trial
26th Oct 2016 07:04
(ShareCast News) - Pharmaceutical giant AstraZeneca reported that its Lynparza drug had positive results from a clinical trial to treat women with mutated ovarian cancer. In a phase-three trial Lynparza tablets were used as a monotherapy to treat platinum-sensitive replaced BRCA-mutated ovarian canc
Read moreFDA accepts review of AstraZeneca drug for hyperkalaemia
18th Oct 2016 07:21
(ShareCast News) - The US Food and Drug Administration has accepted a complete re-submission of a new drug application for sodium zirconium cyclosilicate (ZS-9), a potential new medicine for the treatment of hyperkalaemia by AstraZeneca's subsidiary ZS Pharma. Hyperkalaemia - high potassium levels i
Read moreThursday broker round-up
13th Oct 2016 13:43
(ShareCast News) - Ted Baker: Goldman Sachs keeps at buy with a target price of 3140p. Brown N: HSBC reiterates hold, 205p target. MITIE: Citigroup keeps at neutral with a 280p target. Prudential: Societe Generale reiterates outperform with a 1250p target. Astrazeneca: Jefferies keeps at buy with
Read moreSunday newspaper round-up: William Hill, Inflation, Ebay
9th Oct 2016 16:00
(ShareCast News) - William Hill and the Canadian owner of the PokerStars gaming website are in talks to create a £5bn betting giant that would storm into the FTSE 100. City sources said negotiations between Britain's biggest high-street bookmaker and Amaya, which bought PokerStars for $4.9bn two yea
Read moreAstraZeneca to divest US rights to nasal spray to J&J affiliate
7th Oct 2016 07:06
(ShareCast News) - Pharmaceutical giant AstraZeneca agreed to divest rights outside the US of its nasal spray to Johnson & Johnson affiliate CilagGmbH International for $330m in order to concentrate on respiratory treatments. AstraZeneca will not maintain an ongoing interest in the Rhinocort Aqua na
Read moreAstrazeneca wins Nice and beta-blocker deals but loses in Brilinta trial
4th Oct 2016 07:07
(ShareCast News) - It was two out of three for Astrazeneca on Tuesday as disappointment over the unsuccessful conclusion of a huge drug trial was offset by a win with the NHS drug regulator for one of its big cancer drugs and a licence deal for a beta-blocker medicine. Dealing with the bad news firs
Read moreTuesday newspaper round-up: AstraZeneca, rental housing, BT, BP
4th Oct 2016 06:57
(ShareCast News) - AstraZeneca has won a major victory in the UK after the country's drugs watchdog approved one of the most important cancer drugs in its oncology portfolio. The National Institute for Health and Care Excellent (Nice) announced on Tuesday that osimertinib, known under the brand name
Read moreAstraZeneca signs drug deal with Allergan
3rd Oct 2016 07:29
(ShareCast News) - AstraZeneca's global biologics research and development arm MedImmune has entered into a licensing agreement with Allergan for the global rights to MEDI2070, which is currently in a Phase IIb clinical trial for moderate-to-severe Crohn's disease and ready for Phase II for ulcerati
Read moreWednesday broker round-up
28th Sep 2016 12:15
(ShareCast News) - Close Brothers Group: Barclays reiterates overweight with a target price of 1500p. Royal Dutch Shell: HSBC keeps at buy, 2050p target. William Hill: Deutsche Bank keeps at buy with a 390p target. The Restaurant Group: Berenberg reiterates hold with a 350p target. Astrazeneca: D
Read more